3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
4
Waldenstrom Macroglobulinemia
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, B-Cell
1
Hematologic Neoplasms
1
Interventions
Rituximab
7
zanubrutinib
6
venetoclax
4
ibrutinib
3
Dexamethasone
3
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Cyclophosphamide
2
Blood Specimen Collection
2
Biopsy
2
Bendamustine Hydrochloride
2
pirtobrutinib
1
obinutuzumab
1
Positron-Emission Tomography
1
Lenalidomide
1
Exercise
1
Diet
1
CT-P10
1
Bortezomib
1
ARQ531
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Waldenstrom Macroglobulinemia
×
ARQ531
×
Clear all
NCT04728893
2026-05-26
MK-1026-003
Merck Sharp & Dohme LLC
Phase 2
Recruiting
490 enrolled